Skip to main content

Decoding Risk in Clinical & Public Health Practice: Absolute vs Relative Risk Reduction

What is the difference between Absolute Risk Reduction (ARR) and Relative Risk Reduction (RRR)? This is a common question from students and clinicians. Understanding these concepts is crucial for interpreting research findings, especially in clinical and public health settings.

Absolute Risk Reduction (ARR) refers to the difference in outcomes between a control group and a treated group in a clinical trial or an public health study.

Formula: ARR = CER - EER

Where: CER is the Control Event Rate (rate of event in the control group) and EER is the Experimental Event Rate (rate of event in the experimental group).

Example: Imagine a trial in which 10% of patients in the control group have an adverse event, and only 5% in the treatment group experience the same.

ARR = 10% - 5% = 5%

This means that the drug reduces the absolute risk of an adverse event by 5%. In total, 20 people need to be treated to prevent one event (the Number Needed to Treat, NNT).

Relative Risk Reduction (RRR) is the proportional reduction in outcomes between the treated and untreated groups. It's a way to contextualize the effectiveness of a treatment by considering the baseline risk.

Formula: RRR = (CER - EER)/{CER} times 100

Example: Continuing with the same drug trial, RRR = (10% - 5%) / (10%) times 100 = 50%

Interpretation: The drug reduces the relative risk of an adverse event by 50% compared to the control group.

Key Differences between ARR and RRR

1. Context: ARR gives you the actual change in risk, which is straightforward and easily interpretable. RRR puts this change in the context of the baseline risk, making the treatment appear seem more effective than it may actually be.

2. Impact: ARR is more useful for understanding the individual benefit of an intervention, while RRR is often more impressive for public health interventions where a small absolute change can have a large impact when scaled up.

3. Communication: RRR is often used in marketing or in media because it tends to produce a larger, more eye-catching number. However, this can be misleading if not used with the ARR, which provides a more direct measure of an intervention's effect.

4. Clinical Relevance: Knowing both ARR and RRR can aid in shared decision-making between clinicians and patients. While RRR can show the effectiveness of a treatment, ARR can guide on how much benefit an individual patient can expect.

By understanding both Absolute Risk Reduction and Relative Risk Reduction, clinicians and public health specialists can better interpret the data from clinical, public and epidemiological studies, and subsequently make more informed decisions about treatment options and public health interventions.

Comments

Post a Comment

Popular posts from this blog

What is the difference between primordial prevention and primary prevention?

Primordial prevention and primary prevention are both crucial strategies for promoting health, but they operate at different levels. Primordial prevention aims to address the root causes of health problems and improve the wider determinants of health. It focuses on preventing the emergence of risk factors in the first place by tackling the underlying social, economic, and environmental determinants of health. This involves broad, population-wide interventions such as: Policies that promote healthy food choices: Think about initiatives like taxing sugary drinks to discourage unhealthy consumption, or providing subsidies for fruits and vegetables to make them more accessible. Urban planning that prioritises well-being: This could include creating walkable neighborhoods with safe cycling routes, ensuring access to green spaces for recreation and relaxation, and designing communities that foster social connections. Social programs that address inequality: Initiatives aimed at reducing pov...
Post a Comment
Read more

Talking to Patients About Weight-Loss Drugs

The use of weight-loss drugs such as GLP-1 receptor agonists (e.g., semaglutide, tirzepatide) has increased rapidly in recent years. These drugs can help some people achieve significant weight reduction, but they are not suitable for everyone and require careful counselling before starting treatment. By discussing benefits, risks, practicalities, and  uncertainties, clinicians can help patients make informed, realistic decisions about their treatment. Key points to discuss with patients 1. Indications and eligibility These drugs are usually licensed for adults with a specific BMI. They should be used alongside lifestyle interventions such as dietary change, increased physical activity, and behaviour modification. 2. Potential side effects – some can be serious Common adverse effects include nausea, vomiting, diarrhoea, and abdominal discomfort. Less common but more serious risks include gallstones, pancreatitis and visual problems. Patients should know what to watch for a...
Post a Comment
Read more

What makes a good doctor – and who gets to decide?

What Makes a Good Doctor? This is the question that Waseem Jerjes and I explore in the Journal of the Royal Society of Medicine . It is a key question that underpins the architecture of medical education, clinical practice, regulation, and professional identity. It cannot be answered by regulators, educators, or employers in isolation. It must be answered together – by doctors and patients – revisited throughout a career, and adapted as society and the profession change. Without that shared reflection, the danger is not simply disillusionment, but the erosion of the moral foundations of clinical work. As we enter an era when diagnosis will increasingly involve artificial intelligence and when performance metrics reward volume over value, reclaiming this question as a professional one is imperative. The integrity of our institutions – and of the practitioners within them – depends on reimagining excellence in inclusive, relational terms. A good doctor is not a flawless technician or a f...
Post a Comment
Read more